纳微科技：股东苏州纳卓、苏州纳研累计减持约675.37万股，减持计划实施完毕

Group 1 - The core revenue composition of Nanwei Technology for the year 2024 is as follows: Biopharmaceuticals account for 65.55%, Analytical Testing for 28.98%, Flat Panel Display for 4.54%, In Vitro Diagnostics for 0.68%, and Other Businesses for 0.25% [1] Group 2 - On August 12, 2025, Nanwei Technology announced that shareholders Suzhou Nazhuo and Suzhou Naresearch completed a share reduction plan, reducing their holdings by a total of 6,753,736 shares, which represents 1.6725% of the company's total share capital [3]